Henry Schein (HSIC)
(Delayed Data from NSDQ)
$70.82 USD
+0.98 (1.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $70.80 -0.02 (-0.03%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.82 USD
+0.98 (1.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $70.80 -0.02 (-0.03%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
Zacks News
Henry Schein (HSIC) Hurt by Macroeconomic Woes, Cyber Attacks
by Zacks Equity Research
With sustained macroeconomic pressure, Henry Schein (HSIC) struggles to keep in check its cost of revenues and operating expenses.
Compared to Estimates, Henry Schein (HSIC) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Henry Schein (HSIC) Q2 Earnings Surpass, 2024 Guidance Slashed
by Zacks Equity Research
Henry Schein's (HSIC) second-quarter results reflect an improvement in sales trends in distribution businesses.
Henry Schein (HSIC) Q2 Earnings Beat Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 0.82% and 4.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Baxter International, Henry Schein and IDEXX Laboratories
by Zacks Equity Research
Baxter International, Henry Schein and IDEXX Laboratories are included in this Analyst Blog.
What's in Store for These 3 MedTech Stocks in Q2 Earnings?
by Urmimala Biswas
MedTech companies' quarterly results are likely to be strong on a sequential basis. Let's see how BAX, HSIC and IDXX are placed ahead of their earnings releases.
Countdown to Henry Schein (HSIC) Q2 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Henry Schein (HSIC) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
McKesson (MCK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dentsply International (XRAY) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of -2% and 1.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Henry Schein (HSIC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Henry Schein (HSIC) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How to Play Henry Schein (HSIC) Ahead of Q2 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is expected to deliver impressive sales in both its businesses in the second quarter of 2024, along with a steady pace of recovery from the cyber incident.
Here's Why Henry Schein (HSIC) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Strength Seen in Henry Schein (HSIC): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
Henry Schein (HSIC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is It Wise to Retain Henry Schein (HSIC) in Your Portfolio Now?
by Zacks Equity Research
Robust acquisitions and a widespread distribution network bode well for Henry Schein's (HSIC) operations.
Henry Schein (HSIC) Banks on Strategic Buyouts Amid Macro Issues
by Zacks Equity Research
Henry Schein's (HSIC) revenue growth is supported by niche acquisitions and partnerships.
4 Stocks to Buy Amid Dental Supplies Industry Challenges
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.
Here's Why Henry Schein (HSIC) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Henry Schein (HSIC) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein (HSIC) Banks on Global Expansion Amid Macro Issues
by Zacks Equity Research
Within the Dental business, Henry Schein (HSIC) is aiming to deliver customized solutions, leveraging market insights and technological advancements.
Here's Why Henry Schein (HSIC) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC), owing to strategic acquisitions and potential in Henry Schein One.
Henry Schein (HSIC) Extends Partnership With Special Olympics
by Zacks Equity Research
Henry Schein's (HSIC) extended collaboration with Special Olympics is likely to promote wellness and health education for athletes with ID around the world.